Updated Results of the SPARTAN Study Show 25 Percent Reduction in the Risk of Death in Patients with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) Treated with ERLEADA ® (apalutamide)

Results from the second interim analysis of the Phase 3 SPARTAN study featured in an oral presentation at ESMO 2019 and simultaneously published in Annals of Oncology
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news